Cargando…

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

BACKGROUND: Angiogenesis is fundamental to the progression of many solid tumours including prostate cancer. Sodium selenate is a small, water-soluble, orally bioavailable activator of PP2A phosphatase with anti-angiogenic properties. METHODS: This was a dose-escalation phase I study in men with asym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corcoran, N M, Hovens, C M, Michael, M, Rosenthal, M A, Costello, A J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939789/ https://www.ncbi.nlm.nih.gov/pubmed/20648008 http://dx.doi.org/10.1038/sj.bjc.6605798

Ejemplares similares

Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
por: Vivash, Lucy, et al.
Publicado: (2021)

A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2022)

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
por: Bratt, O, et al.
Publicado: (2009)

Safety and efficacy of sodium selenate as feed additive for ruminants
por: Bampidis, Vasileios, et al.
Publicado: (2019)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2020)

Sodium selenate as a therapeutic for tauopathies: A hypothesis paper
por: Dilcher, Roxane, et al.
Publicado: (2022)

MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
por: Tsang, Amanda, et al.
Publicado: (2020)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
por: Kolinsky, M.P., et al.
Publicado: (2020)

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2017)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
por: Vivash, Lucy, et al.
Publicado: (2021)

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
por: Chaker, A. M., et al.
Publicado: (2016)

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
por: Morris, Michael J., et al.
Publicado: (2019)

Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
por: Aggarwal, Rahul, et al.
Publicado: (2023)

Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol
por: Vivash, Lucy, et al.
Publicado: (2023)

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study
por: Lorenz, Hanns-Martin, et al.
Publicado: (2011)

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
por: Diab, Adi, et al.
Publicado: (2022)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression
por: Stuchbery, Ryan, et al.
Publicado: (2016)

An Open‐label Phase 1 Dose‐escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
por: Marconato, L., et al.
Publicado: (2015)

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy
por: Casillas-Espinosa, Pablo M, et al.
Publicado: (2023)

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
por: Ali, H., et al.
Publicado: (2022)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

Sodium selenate regulates the brain ionome in a transgenic mouse model of Alzheimer’s disease
por: Zheng, Lin, et al.
Publicado: (2016)

Rice seed priming with sodium selenate: Effects on germination, seedling growth, and biochemical attributes
por: Du, Bin, et al.
Publicado: (2019)

Joint Cultivation of Allium ursinum and Armoracia rusticana under Foliar Sodium Selenate Supply
por: Amagova, Zarema, et al.
Publicado: (2022)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
por: de Boer, Nadine Leonie, et al.
Publicado: (2019)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
por: Lin, Chia-Chi, et al.
Publicado: (2019)

Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
por: Wang-Gillam, Andrea, et al.
Publicado: (2023)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer
por: Sapre, Nikhil, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_34ctkaccuer5qose82u967v7sa